User:TheBioMajor/Colitis
 | This is the sandbox page where you will draft your initial Wikipedia contribution.
If you're starting a new article, you can develop it here until it's ready to go live. If you're working on improvements to an existing article, copy only one section at a time of the article to this sandbox to work on, and be sure to use an edit summary linking to the article you copied from. Do not copy over the entire article. You can find additional instructions here. Remember to save your work regularly using the "Publish page" button. (It just means 'save'; it will still be in the sandbox.) You can add bold formatting to your additions to differentiate them from existing content. |
Article Draft[edit]
Lead[edit]
Article body[edit]
In the lab, the CRISPR-Cas systems effectively killed C. difficile bacteria. Researchers tested this approach in mice infected with C. difficile. Two days after the CRISPR treatment, the mice showed reduced C. difficile levels. Next steps include retooling the phage to prevent C. difficile from returning after the initial effective killing.[1]
In 2022 Yang et al. published a report on a successful treatment, using mesenchymal stem cells, of experimental colitis in mice.[2]
Additional research was conducted by Huang et al. that analyzed specific genes and biological markers that are associated with the risk of colon cancer development in patients with colitis. The results showed a correlation between certain biomarkers and the development of disease.[3]
[3][4]References[edit]
References[edit]
- ^ "Study shows CRISPR effectiveness against colitis pathogen". medicalxpress.com. Retrieved 2020-03-13.
- ^ Yang, Fan; Ni, Beibei; Liu, Qiuli; He, Fangping; Li, Li; Zhong, Xuemei; Zheng, Xiaofan; Lu, Jianxi; Chen, Xiaoyan; Lin, Huizhu; Xu, Ruixuan; He, Yizhan; Zhang, Qi; Zou, Xiaoguang; Chen, Wenjie (2022). "Human umbilical cord-derived mesenchymal stem cells ameliorate experimental colitis by normalizing the gut microbiota". Stem Cell Research & Therapy. 13 (1): 475. doi:10.1186/s13287-022-03118-1. PMC 9476645. PMID 36104756.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ a b Huang, Yongming; Zhang, Xiaoyuan; PengWang; Li, Yansen; Yao, Jie (2022-06-22). "Identification of hub genes and pathways in colitis-associated colon cancer by integrated bioinformatic analysis". BMC Genomic Data. 23 (1): 48. doi:10.1186/s12863-022-01065-7. ISSN 2730-6844. PMC 9219145. PMID 35733095.
{{cite journal}}: CS1 maint: PMC format (link) CS1 maint: unflagged free DOI (link) - ^ Kozik, Ariangela J.; Nakatsu, Cindy H.; Chun, Hyonho; Jones-Hall, Yava L. (2019-11-08). Power, Krista (ed.). "Comparison of the fecal, cecal, and mucus microbiome in male and female mice after TNBS-induced colitis". PLOS ONE. 14 (11): e0225079. doi:10.1371/journal.pone.0225079. ISSN 1932-6203. PMC 6839838. PMID 31703107.
{{cite journal}}: CS1 maint: PMC format (link) CS1 maint: unflagged free DOI (link)